Kenneth Gordon to Clinical Trials as Topic
This is a "connection" page, showing publications Kenneth Gordon has written about Clinical Trials as Topic.
Connection Strength
0.709
-
Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370.
Score: 0.465
-
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022 03; 186(3):466-475.
Score: 0.135
-
Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013 Jul; 9(7):677-82.
Score: 0.075
-
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
Score: 0.018
-
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011 Mar; 10(3):289-300.
Score: 0.016